Core Insights - 60 Degrees Pharmaceuticals, Inc. has announced a partnership with GoodRx to provide savings of up to 30% on ARAKODA (tafenoquine) for eligible consumers [1][10] - ARAKODA is the only FDA-approved, once-weekly malaria prevention medication available in the U.S. market, making it a preferred choice for travelers to malaria-endemic regions [2][6] Company Overview - 60 Degrees Pharmaceuticals, Inc. specializes in developing new medicines for vector-borne diseases and received FDA approval for ARAKODA in 2018 [19] - The company is headquartered in Washington, D.C., and has a subsidiary in Australia, with ARAKODA commercially available in both countries [19] Product Information - ARAKODA (tafenoquine) is indicated for malaria prophylaxis in patients aged 18 and older and has a long terminal half-life of approximately 16 days, allowing for less frequent dosing [7][8] - The medication was discovered by the Walter Reed Army Institute of Research and has undergone extensive safety assessments in clinical trials [5][6] Partnership Details - The collaboration with GoodRx aims to lower out-of-pocket costs for patients and expand the marketing reach of ARAKODA, making it accessible at over 70,000 pharmacies nationwide [10][4] - Eligible patients can access a low self-pay price for ARAKODA through GoodRx starting February 2, 2026 [4][10]

Core Viewpoint - 60 Degrees Pharmaceuticals, Inc. is initiating the regulatory process to gain access to the U.S. market for Australian Chestnut Extract as a botanical product for non-prescription uses [1][5]. Group 1: Company Developments - The company has exercised its option with Florida State University to negotiate an exclusive license for large-scale purification techniques to extract castanospermine from Australian Chestnut seeds [1]. - Since signing the option agreement in April 2025, the company has conducted safety testing on Australian Chestnut Extract and developed various prototype capsule formulations for oral delivery [5]. - 60 Degrees Pharmaceuticals specializes in developing new medicines for vector-borne diseases and received FDA approval for its lead product, ARAKODA, in 2018 [6]. Group 2: Product Information - Castanospermum australe, the source of castanospermine, is primarily found in Queensland and New South Wales, Australia, as well as in Florida, Hawaii, and California [2]. - Castanospermine has been shown to modulate carbohydrate metabolism and impact disease outcomes in animal models through immunomodulation [3]. - It is also a metabolite of celgosivir, which has been evaluated in clinical trials against HIV and Hepatitis C, suggesting castanospermine's safety and activity against similar pharmacological targets [4].

Company Performance - Spring Valley Acquisition Corp. III Warrants (NASDAQ:SVACW) experienced a significant price increase of 294.23%, reaching $2.05, potentially driven by speculative trading or news related to their energy and decarbonization operations [1][6] - 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) saw its stock price rise by 144.5% to $4.89, likely benefiting from positive clinical trial developments or regulatory approvals, despite a 1-4 reverse stock split leading to a 2.4% decline ahead of the event [2] - IO Biotech, Inc. (NASDAQ:IOBT) had a stock price increase of 102.12%, reaching $0.41, with investor optimism possibly fueled by its focus on immune-modulating cancer therapies and exploration of strategic alternatives [3][6] - Namib Minerals Warrants (NASDAQ:NAMMW) recorded an 88.68% increase to $0.34, influenced by its involvement in gold and critical green metals production and exploration, while Namib Minerals Ordinary Shares (NASDAQ:NAMM) rose by 77.47% to $4.01, possibly due to favorable mining outcomes or strategic acquisitions [4] Market Dynamics - The recent stock price movements highlight the dynamic nature of the market, where company developments, industry trends, and investor sentiment play crucial roles in influencing stock prices [5]

Core Insights - 60 Degrees Pharmaceuticals, Inc. has announced a partnership with Runway Health to enhance access to ARAKODA (tafenoquine) for malaria prevention among international travelers [1][4] - ARAKODA is the only broad-spectrum, once-weekly prescription malaria prevention medication available in the U.S. market [2][9] - The partnership will commence on April 2, 2026, and aims to provide a personalized medical treatment plan for travelers [4] Company Overview - 60 Degrees Pharmaceuticals, Inc. specializes in developing new medicines for vector-borne diseases and received FDA approval for ARAKODA in 2018 [18] - The company is headquartered in Washington, D.C., and has a subsidiary in Australia, with ARAKODA commercially available in both countries [18] Product Information - ARAKODA (tafenoquine) is indicated for malaria prophylaxis in adults aged 18 and older and has been assessed for safety in multiple clinical trials [5][8] - The drug has a long terminal half-life of approximately 16 days, allowing for less frequent dosing [7] - ARAKODA is prescribed in a loading phase of 2 x 100 mg tablets once daily for three days before travel, followed by 2 x 100 mg tablets weekly during travel [7] Partnership Details - The collaboration with Runway Health will utilize a telehealth platform to facilitate online consultations and home delivery of ARAKODA before travel [2][4] - This partnership adds a consumer-focused approach to the marketing strategy of ARAKODA, targeting individuals planning to travel to malaria-endemic regions [9]

Core Viewpoint - 60 Degree Pharmaceuticals, Inc. will implement a one-for-four (1:4) reverse stock split to comply with Nasdaq's minimum bid price requirement, effective January 20, 2026 [1][2] Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from approximately 5,148,767 to about 1,287,192 [5] - All issued and outstanding shares, options, restricted stock awards, warrants, and other securities will be adjusted accordingly, with no fractional shares issued [4] - The par value of the Common Stock will remain unchanged at $0.0001 per share, and the authorized number of shares will not change [4] Group 2: Approval Process - Stockholders approved the reverse split proposal at a special meeting on October 8, 2025, allowing the board to file an amendment to effect the split [3] - The board officially approved the reverse split on December 17, 2025, and the amendment has been filed with the Secretary of State of Delaware [3] Group 3: Company Overview - 60 Degrees Pharmaceuticals, Inc. specializes in developing new medicines for vector-borne diseases and received FDA approval for its lead product, ARAKODA, in 2018 [6] - The company is headquartered in Washington, D.C., with a subsidiary in Australia and collaborates with prominent research organizations [6]

Core Insights - 60 Degrees Pharmaceuticals, Inc. announced a study revealing that 24% of 50 patients with chronic fatigue were infected with Babesia, a parasite linked to babesiosis, suggesting a potential connection between Babesia infection and prolonged recovery times in chronic fatigue patients [1][2][9] Group 1: Study Findings - The study conducted by North Carolina State University involved 50 participants who reported chronic diseases and potential exposure to arthropod vectors, with all participants experiencing fatigue for at least six months [5] - The findings support the hypothesis that Babesia infection may be associated with chronic diseases, particularly in prolonging recovery times for patients suffering from chronic fatigue [2][4] Group 2: Ongoing Research - The B-Free Chronic Babesiosis Study is currently evaluating the efficacy and safety of the ARAKODA regimen (tafenoquine) over 90 days for resolving severe fatigue in chronic babesiosis patients, with enrollment taking place at the Icahn School of Medicine at Mount Sinai in New York [3][9] - The study's results highlight the need for further prospective controlled studies to better understand the relationship between Babesia infection and chronic diseases [4] Group 3: Babesiosis Overview - Babesiosis is a tick-borne illness caused by Babesia parasites, leading to symptoms such as fevers, chills, and fatigue, with severe cases posing life-threatening risks, especially to the elderly and immunosuppressed [7] - The incidence of babesiosis is rapidly increasing, particularly in the Northeast, with an estimated minimum annual incidence of at least 25,000 cases in the U.S., although the actual number may be significantly higher [7][8] Group 4: Company Background - 60 Degrees Pharmaceuticals, Inc. specializes in developing new medicines for vector-borne diseases and received FDA approval for its lead product, ARAKODA (tafenoquine), for malaria prevention in 2018 [10] - The company collaborates with prominent research and academic organizations in the U.S. and Australia, and is headquartered in Washington, D.C. [10]

Core Viewpoint - Shares of 60 Degrees Pharmaceuticals Inc. (SXTP) have recently declined by 19.7% over the past two weeks, but the formation of a hammer chart pattern suggests potential support and a possible trend reversal in the future [1] Technical Analysis - The hammer chart pattern indicates a minor difference between opening and closing prices, with a long lower wick, suggesting that the stock may have found support after a downtrend [4][5] - This pattern typically signals that bears may have lost control, indicating a potential trend reversal as buying interest emerges [5] Fundamental Analysis - There has been a positive trend in earnings estimate revisions for SXTP, which is considered a bullish indicator, as it often leads to price appreciation [7] - The consensus EPS estimate for the current year has increased by 20.8% over the last 30 days, indicating that analysts expect better earnings than previously predicted [8] - SXTP currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9][10]

Core Insights - 60 Degrees Pharmaceuticals, Inc. plans to expand its sales and marketing initiatives for ARAKODA® following positive results from a 6-month commercial pilot that indicated increased market demand among prescribers [1][2][3] Sales and Marketing Initiatives - The company will enhance its integrated digital marketing campaign to improve awareness and engagement with prescribers [2] - The number of inside sales representatives will be increased to strengthen outreach and provider relationships [8] - A partnership with GoodRx will be established to provide broader visibility of ARAKODA offers, facilitating access to savings information for patients and prescribers [8] Clinical Development - The company will add at least two clinical sites for ongoing studies related to babesiosis treatment, responding to FDA feedback regarding its Breakthrough Therapy Designation request [3][4] - The FDA acknowledged that babesiosis meets the criteria for being classified as a serious disease, suggesting the company resubmit its request with data from ongoing clinical trials [3] Product Information - ARAKODA® (tafenoquine) is approved for malaria prophylaxis in the U.S. and has been assessed for safety in five randomized trials lasting up to six months [5][6][20] - Tafenoquine offers potential advantages in less-frequent dosing for malaria prophylaxis due to its long terminal half-life of approximately 16 days [10]

Core Insights - 60 Degrees Pharmaceuticals, Inc. has initiated patient enrollment for the B-FREE Chronic Babesiosis Study, the first of its kind to evaluate a therapeutic for chronic babesiosis, which is expected to run for approximately 12 months [1][5][7] Study Overview - The B-FREE Chronic Babesiosis Study (NCT06656351) is a Phase 2 open-label study assessing the efficacy and safety of the ARAKODA® regimen of tafenoquine over 90 days for patients with chronic babesiosis [2][6] - Chronic babesiosis is characterized by disabling fatigue lasting at least six months, with laboratory confirmation of Babesia parasite exposure within the last year [3][4] - The study aims to confirm Babesia infection using validated molecular tests, potentially revealing a patient population size that could range from 4,400 to 190,000 cases annually in the U.S. [4][7] Treatment Details - The primary endpoint of the study is the resolution of fatigue, measured at Day 90 compared to baseline, using a patient-reported outcome measure [6][7] - The treatment regimen involves self-administering tafenoquine (2 x 100 mg tablets) orally with food for a total of 12 weeks [6][7] Market Need - There is currently no FDA-approved treatment for babesiosis, highlighting a significant unmet medical need [4][15] - The incidence of babesiosis is rising, particularly in the Northeast U.S., with estimates suggesting at least 25,000 cases annually, though the true number may be much higher [15][30] Company Background - 60 Degrees Pharmaceuticals, Inc. specializes in developing new medicines for vector-borne diseases and achieved FDA approval for ARAKODA® (tafenoquine) for malaria prevention in 2018 [30][18] - The company collaborates with research and academic organizations in the U.S. and Australia, and is headquartered in Washington, D.C. [30]

Core Viewpoint - 60 Degrees Pharmaceuticals, Inc. reported significant growth in net product revenue for Q3 2025, alongside challenges in gross profit due to inventory write-offs and increased operating expenses [6][7]. Financial Highlights for Q3 2025 - Net product revenue increased by 223% year-over-year to $438 thousand [6]. - Gross profit decreased from $24 thousand to a loss of $100 thousand due to a one-time inventory write-off [6][7]. - Operating expenses rose to approximately $2.32 million, up from $2.16 million in Q3 2024, primarily due to increased advertising and sales promotion costs [7]. - Net loss attributable to common shareholders was approximately $2.44 million, or ($0.66) per share, compared to a net loss of approximately $2.27 million, or ($4.65) per share in Q3 2024 [7]. Business Highlights for Q3 2025 - ARAKODA® pharmacy deliveries increased by 14% from 1,319 boxes in Q3 2024 to 1,505 boxes in Q3 2025 [7]. - The company announced its intention to seek a Minor Use Minor Species (MUMS) designation from the FDA for treating acute canine babesiosis [7]. - A nationwide survey determined the total addressable market (TAM) for Babesiosis treatment to be up to $1.1 billion through patent expiration in 2035 [7]. - The company entered a sponsored research agreement with Tulane University to evaluate tafenoquine's activity against Borrelia and Bartonella bacteria [7]. - A partnership was established with the Icahn School of Medicine at Mount Sinai for a planned Phase II clinical study of tafenoquine in treating chronic babesiosis [7].